Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Terns Pharmaceuticals (Nasdaq: TERN) announced equity inducement awards granted to two new employees effective November 1, 2025 under the 2022 Employment Inducement Award Plan.
The company granted options to purchase a total of 252,500 shares of common stock with a 10-year term and an exercise price of $8.26 per share (closing price on October 31, 2025). The options vest over four years, subject to continued service, and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction 47 Alerts
On the day this news was published, TERN gained 4.36%, reflecting a moderate positive market reaction. Argus tracked a peak move of +25.5% during that session. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $68M to the company's valuation, bringing the market cap to $1.64B at that time.
Data tracked by StockTitan Argus on the day of publication.
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Terns.
The Company granted options to purchase 252,500 shares, in the aggregate, of Terns common stock to the new employees. The options have a 10-year term and an exercise price per share equal to
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program, TERN-701, is a highly selective, oral, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for chronic myeloid leukemia. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Kaytee Bock
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
What did Terns (TERN) announce on November 4, 2025 about employee equity awards?
What is the exercise price and term of the Terns (TERN) inducement options granted November 1, 2025?
How do the Terns (TERN) options vest that were granted as inducements in November 2025?
Why were the Terns (TERN) equity awards approved under Nasdaq Listing Rule 5635(c)(4)?
How many shares did each new employee receive in Terns (TERN) inducement options on November 1, 2025?
